BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Talks.cam//talks.cam.ac.uk// X-WR-CALNAME:Talks.cam BEGIN:VEVENT SUMMARY:Protein Kinase Regulation by the HSP90 Molecular Chaperone System - Professor Laurence Pearl\; University of Sussex DTSTART:20220720T123000Z DTEND:20220720T133000Z UID:TALK175541@talks.cam.ac.uk CONTACT:Bobbie Claxton DESCRIPTION:Abstract:\nThe HSP90 molecular chaperone\, in collaboration wi th its co-chaperone CDC37 plays a critical role in the cellular stabilisat ion\, activation and regulation of a substantial proportion of the kinome\ , including most of the protein kinases that drive development and progres sion of cancer. Work from our lab and others over several decades has reve aled some of the mechanisms by which HSP90-CDC37 engages with its protein kinase clients\, how this affects their structure and activity\, and how d rugs targeted at HSP90 and its kinase clients can modulate this. In this t alk I will summarise what we know about HSP90-CDC37 interactions with prot ein kinases\, discuss the discovery and characterisation of a novel E3 ubi quitin ligase that mediates kinase degradation when HSP90 function is impa ired\, and present new results that show how HSP90-CDC37 facilitates compr ehensive dephosphorylation and ‘factory reset’ of client protein kinas es by the protein phosphatase PP5.\n\nBiography:\nLaurence Pearl is Profes sor of Structural Biology in the Genome Damage and Stability Centre at the University of Sussex\, where he was Head of the School of Life Sciences f rom 2009 to 2017\, and is also Head of the Division of Structural Biology at The Institute of Cancer Research in London. His laboratory studies the structural biology of the DNA Damage Response and the HSP90 molecular chap erone system\, and seeks to translate these basic studies for the developm ent of new drugs for the treatment of cancer and other diseases. He is a F ellow of the Royal Society (FRS)\, a Fellow of the Academy of Medical Scie nces (FMedSci) and an elected member of the European Molecular Biology Org anisation (EMBO) and the Academia Europeae. In 2013 he shared the CR-UK Tr anslational Cancer Research Prize (with Paul Workman\, ICR) for uncovering HSP90 as a novel target in cancer therapy and for the development of the leading HSP90 inhibitor\, AUY922. He was awarded the 2018 Novartis Medal a nd Prize by the Biochemical Society.\n\nClick here to join live - https:// us06web.zoom.us/j/83547914899 LOCATION:Online via zoom &\; Kings Hedges Room END:VEVENT END:VCALENDAR